Human trial
TRIUMPH-2: peer-reviewed Phase 3 results (September 2026)
Adults with obesity and type 2 diabetes; published online September 29, 2026.
Reported findings. TRIUMPH-2 randomized 1,152 adults with obesity and type 2 diabetes. At week 80, mean weight change in the treatment-regimen estimand was -11.9%, -16.8% and -18.8% across the experimental arms versus -5.1% with placebo; glycemic control also improved.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Gastrointestinal adverse events, hypotension and dysesthesia were more frequent with retatrutide. Discontinuation due to adverse events or death was 12% and 8% in two experimental arms, versus 4% in the other arm and 5% with placebo. Investigators considered all reported deaths unrelated to study intervention.
Limits. Sponsor-funded trial of controlled study material. Results do not establish approval or equivalence of commercial research preparations. Different statistical estimands yield different headline weight-loss percentages.
Preparation: Source preparation; commercial equivalence unverified. Route: subcutaneous
Read original source ↗Editorial review 2026-10-09. Clinician review pending.